Eutilex Co., Ltd. – Trademark Portfolio
Entity Type: 03
Eutilex Co., Ltd. holds 10 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 8 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 3 Nice Classification classes. Currently, 6 trademarks are registered. Notable registered marks include TAST, GIPICA, ALPITERO, and KARRATIO. The owner is based in Seoul.
Suite #408,
58, Gasan digital 1-ro, Geumcheon-gu,
Seoul 08591 , KR
Showing of trademarks Trademarks
Trademark Classifications
Eutilex Co., Ltd.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific and technological services; industrial analysis and research services
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Frequently Asked Questions
How many trademarks does Eutilex Co., Ltd. have?
Eutilex Co., Ltd. has 10 U.S. trademarks filed with the USPTO. Of these, 6 registered, 1 abandoned, 1 cancelled.
What trademark classes does Eutilex Co., Ltd. file in?
Eutilex Co., Ltd. files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Eutilex Co., Ltd.'s most well-known trademarks?
Eutilex Co., Ltd.'s registered trademark portfolio includes well-known marks such as TAST, GIPICA, ALPITERO, and KARRATIO. These are among 6 currently registered trademarks in the portfolio.
What is Eutilex Co., Ltd.'s trademark registration success rate?
Eutilex Co., Ltd. has a 75% trademark registration rate, with 6 out of 8 resolved applications resulting in successful registration. Currently, 0 applications are pending review.